Saudi Arabia is expanding its ambitions in advanced therapies through Vision 2030, focusing on building local biomanufacturing capabilities and accelerating access to cell and gene therapies.

This discussion examines how next‑gen platforms and predictive modelling approaches provide the process insight to drive consistency, yield, and potency as programs move towards commercialization.

This session is designed for cell and gene therapy developers, process development teams, and manufacturing leaders seeking to accelerate timelines while reducing manufacturing costs.

US biotech companies expanding clinical trials into the EU and UK face complex regulatory and logistics challenges. Damian Larington shares key requirements, common mistakes and emerging trial trends.

Teknova leverages their modular manufacturing platform to help novel therapy developers across cell and gene therapy, mRNA, and next-generation antibodies accelerate their breakthroughs.

Hear how Marken is rising to constant global disruptions — embracing innovation, reducing risk, and building future-ready solutions that balance speed, cost, and control.

One of the biggest hurdles sponsors face is finding a CDMO with true commercial AAV experience—partners who have successfully taken them through global approvals into the commercial market.

Limula is addressing the challenges of clinical centres and biotech companies looking for a solution enabling fully automated production of cell therapies at the point-of-care.

As a cell therapy advances to commercial-scale manufacturing, success depends on strategic partnerships that ensure quality, consistency, and regulatory compliance while enabling scalability.

In a complex, volatile global market, manufacturability is no longer something to address “when the time comes”-it must be built into the therapy from day one